menu search

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented. INB-100 continues to demonstrate a favorable safety profile with no dose-limiting toxicities (DLTs) and evidence of robust gamma-delta T cell […] The post IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematol... Read More
Posted: Nov 2 2023, 13:17
Author Name: forextv
Views: 112148

Search within

Pages Search Results: